Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report
- PMID: 29096801
- DOI: 10.1016/j.jacc.2017.09.015
Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report
Abstract
Background: Post-market surveillance is needed to evaluate the real-world clinical effectiveness and safety of U.S. Food and Drug Administration-approved devices.
Objectives: The authors examined the commercial experience with transcatheter mitral valve repair for the treatment of mitral regurgitation.
Methods: Data from the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy Registry on patients commercially treated with transcatheter mitral valve repair were analyzed. The study population consisted of 2,952 patients treated at 145 hospitals between November 2013 and September 2015. In 1,867 patients, data were linked to patient-specific Centers for Medicare and Medicaid Services administrative claims for analyses.
Results: The median age was 82 years (55.8% men), with a median Society of Thoracic Surgery predicted risk of mortality of 6.1% (interquartile range: 3.7% to 9.9%) and 9.2% (interquartile range: 6.0% to 14.1%) for mitral repair and replacement, respectively. Overall, in-hospital mortality was 2.7%. Acute procedure success occurred in 91.8%. Among the patients with Centers for Medicare and Medicaid Services linkage data, the mortality at 30 days and at 1 year was 5.2% and 25.8%, respectively, and repeat hospitalization for heart failure at 1 year occurred in 20.2%. Variables associated with mortality or rehospitalization for heart failure after multivariate adjustment were increasing age, lower baseline left ventricular ejection fraction, worse post-procedural mitral regurgitation, moderate or severe lung disease, dialysis, and severe tricuspid regurgitation.
Conclusions: Our findings demonstrate that commercial transcatheter mitral valve repair is being performed in the United States with acute effectiveness and safety. Our findings may help determine which patients have favorable long-term outcomes with this therapy.
Keywords: mitral regurgitation; outcomes; transcatheter.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
First TMVR Enters U.S. Market as a Therapy, and a Gateway.J Am Coll Cardiol. 2017 Nov 7;70(19):2328-2329. doi: 10.1016/j.jacc.2017.09.1081. J Am Coll Cardiol. 2017. PMID: 29096802 No abstract available.
Similar articles
-
Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry.JACC Cardiovasc Interv. 2018 Apr 9;11(7):693-702. doi: 10.1016/j.jcin.2018.01.245. JACC Cardiovasc Interv. 2018. PMID: 29622149
-
2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.Ann Thorac Surg. 2017 Mar;103(3):1021-1035. doi: 10.1016/j.athoracsur.2016.12.001. Epub 2016 Dec 9. Ann Thorac Surg. 2017. PMID: 27955994
-
2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.J Am Coll Cardiol. 2017 Mar 14;69(10):1215-1230. doi: 10.1016/j.jacc.2016.11.033. Epub 2016 Dec 9. J Am Coll Cardiol. 2017. PMID: 27956264
-
Insights from the early experience of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.JACC Cardiovasc Interv. 2015 Mar;8(3):377-381. doi: 10.1016/j.jcin.2014.09.022. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703888 Review.
-
Minimum Core Data Elements for Transcatheter Mitral Therapies: Scientific Statement by PASSION CV, HVC, and TVTR.JACC Cardiovasc Interv. 2023 Jun 26;16(12):1437-1447. doi: 10.1016/j.jcin.2023.03.034. JACC Cardiovasc Interv. 2023. PMID: 37380225 Review.
Cited by
-
Outcomes and Complications of Mitral and Tricuspid Transcatheter Edge-to-edge Repair.Interv Cardiol. 2024 Oct 28;19:e20. doi: 10.15420/icr.2024.08. eCollection 2024. Interv Cardiol. 2024. PMID: 39569385 Free PMC article. Review.
-
Transcatheter Edge-to-Edge Repair for Acute Mitral Regurgitation due to Postinfarction Papillary Muscle Rupture.J Soc Cardiovasc Angiogr Interv. 2022 Aug 9;1(5):100431. doi: 10.1016/j.jscai.2022.100431. eCollection 2022 Sep-Oct. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39131457 Free PMC article.
-
Transcatheter Treatment Options for Functional Mitral Regurgitation: Which Device for Which Patients?Interv Cardiol. 2024 Jul 3;19:e10. doi: 10.15420/icr.2021.29. eCollection 2024. Interv Cardiol. 2024. PMID: 39081829 Free PMC article. Review.
-
Insight from International Guidelines: do We Have Satisfactory Recommendations for Secondary Mitral Regurgitation?Rev Cardiovasc Med. 2022 May 17;23(5):180. doi: 10.31083/j.rcm2305180. eCollection 2022 May. Rev Cardiovasc Med. 2022. PMID: 39077618 Free PMC article. Review.
-
Newer versus Early Generation of the MitraClip for Primary Mitral Regurgitation: A Japanese Single-Center Experience.Rev Cardiovasc Med. 2023 May 5;24(5):138. doi: 10.31083/j.rcm2405138. eCollection 2023 May. Rev Cardiovasc Med. 2023. PMID: 39076737 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
